Get started

DXCM

Dexcom Plummets 10% on Raising Its Sales Guidance For The Year Dexcom ( NASDAQ:DXCM ) stock ended Friday's trading session on a rough slate despite the company's first-quarter beat and boosted sales guidance. Sales guidance, however, was light at the midpoint and Dexcom ( NASDAQ:DXCM ) stock plummeted 10%, closing at 124.34. easily boycotting a recent buy point at 132.03 out of a flat base. Some analysts noted that the lion's share of Dexcom's first-quarter growth came from its international segment, while U.S. sales were largely in line with historical seasonal trends. Dexcom ( NASDAQ:DXCM ) makes continuous glucose monitors, or CGMs. These body-worn devices help people with diabetes keep tabs on their blood sugar in real time — a critical component to managing the disease. Dexcom Stock: Solid Beat In the first quarter, Dexcom's ( NASDAQ:DXCM ) sales surged 24% to $921 million. Organically, sales climbed 25% year over year. That easily beat expectations for $910 million, according to FactSet. Further, adjusted earnings came in at 32 cents per share, a nickel above forecasts, and nearly double the 17 cents a share the company reported in the year-earlier period. Dexcom ( NASDAQ:DXCM ) also raised the lower boundary of its guidance for the year, and now expects $4.2 billion to $4.35 billion in sales. The midpoint is slightly below Dexcom stock analysts' forecast for $4.33 billion. Dexcom ( NASDAQ:DXCM ) further noted a record number of new patients started using Dexcom's CGMs during the first quarter and there's been "significant interest" in Stelo, Andrew said. Stelo, Dexcom's newest CGM, will launch this summer for patients with type 2 diabetes who don't require insulin treatment. The device will be available without a prescription, meaning it will likely see some uptake among non-diabetics.
NASDAQ:DXCMShort
by DEXWireNews
GEHC topped out in an ascending channel SHORTGEHC is a new spinoff from General Electric. It has great success thus far with good earnings reports and no dependency on debt and interest rates. It has been on an uptrend since the November earnings. At present it is correcting. I will play this going short on shares while hedging with a long term call options. I am in GE calls out into 2026. A long term call option will yield a lower capital gains tax if closed beyond 12 months. Accordingly, I will go out 15-16 months as I typically want to close early to avoid the effects of time decay. I have high expectations for GEHC. I do not think it will disappoint. When price reaches the running mean anchored VWAP I will close the shares and run only the options.
NASDAQ:GEHCLong
by AwesomeAvani
IRTC Med Tech Device Manufacturer at Fair Value LONGIRTC on the weekly chart shows a symmetrical triangle with compression of price into the apex confluent with the 5 year anchored mean VWAP. I am very familiar with the product line including often lifesaving technology such as AEDs. The company has had weak earnings reports but price has managed to so from undervalued to fair value. I will add to my position here with 20% more. Targets of 140 and 205 are tool drawn onto the chart from pivots of the past. Medical technology is reportedly a hot sector for 2024.
NASDAQ:IRTCLong
by AwesomeAvani
ZBH a medical device company falls on earnings beat LONGZBH is a big global medical device company. It is old school. Aluminum titanium polymers, plates screws wires. Hollywood stars are familiar as it makes the devices for leg lengthening surgery. ( shortening is easy, lengthening not so much) I am familiar because in the past I have served as a consultant for this company. It business is mainly orthopedic elective surgery in supporting orthopedic surgeons serving their patients spine straightening to braces for after a neck fracture. Not a surprise but a lot of surgeries were put off during Covid. So much that the catching up is still ongoing. This is part of the reason why healthcare and the medical technology sectors are expected to be among the hottest of 2024. So much for fundamentals, the technical analysis support for a long trade is commented on the chart. On it you can see the trend since the last earnings. ZBH reported Thursday, January 7th. with an earnings beat and a dip in preparation for a possible rip. The lunch hour of Thursday's session would be the next best time while another time is when you find another dip after you have read this. Want to trade and hedge your trade? Just take a trade in SYK and let them have a race. Cut the underperformer and use the proceeds to get more of the other. It's a very simple plan. Want a broad trade in medical technology? Take a look at XBI or leveraged LABU.
NYSE:ZBHLong
by AwesomeAvani
DexCom (DXCM) Beats on Q3 Earnings, Raises Sales OutlookDexCom, Inc. DXCM reported third-quarter 2023 adjusted earnings per share (EPS) of 50 cents, which beat the Zacks Consensus Estimate of 22 cents by 47.1%. The company reported earnings of 28 cents per share in the prior-year quarter. DXCM registered GAAP net income per share of 29 cents, up from the year-ago quarter’s figure of 24 cents. Shares of DexCom rose 17% in after-hours trading on Oct 26, following better-than-expected quarterly results. However, the stock has lost 28.4% year to date compared with the industry’s 15.5% decline. The broader S&P 500 Index has moved up 10% in the same period. Revenue Details Total revenues grew 27% (26% on an organic basis) to $975 million on a year-over-year basis and beat the Zacks Consensus Estimate by 4%. Strong revenue growth was driven by rising volumes on the back of increasing global awareness of the benefits of real-time Continuous Glucose Monitoring and strong customer additions. Segmental Details Sensor and other revenues(90% of total revenues) increased 31% on a year-over-year basis to $873.8 million. Hardware revenues (10%) decreased 2% year over year to $101.2 million. Geographical Details U.S. revenues (73% of total revenues) increased 24% on a year-over-year basis to $713.6 million. International revenues (27%) improved 33% (30% on an organic basis) year over year to $261.4 million. Margin Analysis Gross profit totaled $623.3 million, up 26.1% from the prior-year quarter’s level. DexCom reported a gross margin (as a percentage of revenues) of 62.7%, which contracted approximately 30 basis points year over year. Research and development expenses amounted to $131.4 million, up 19.1% year over year. Selling, general and administrative expenses totaled $284.7 million, up 21.4% year over year. The company reported total operating expenses of $417.8 million, up 20.5% from the prior-year period’s recorded number. Operating margin (as a percentage of revenues) was 21.1%, up 190 bps year over year. Financial Position DXCM exited the third quarter with $3.24 billion in cash, cash equivalents and marketable securities compared with $3.64 billion in the preceding quarter. Total assets amounted to $6.6 billion compared with $6.82 billion on a sequential basis. 2023 Guidance DexCom raised its guidance for 2023 revenues and also raised its adjusted gross and operating margin outlook. The company now expects revenues in the range of $3.575-$3.6 billion, implying 23-24% year-over-year growth. The Zacks Consensus Estimate for the same is pegged at $3.55 billion. Previously, DXCM expected revenues in the range of $3.5-$3.55 billion. DXCM now expects an adjusted gross margin of approximately 64% versus 63% previously. Adjusted operating margin is projected to be approximately 19%, up from the previous guidance of 17%. DXCM also announced a share repurchase program worth $500 million. Wrapping Up DexCom exited third-quarter 2023 on a strong note, wherein both earnings and revenues beat their respective estimates. Impressive contributions from the Sensor segment, and domestic and international revenue growth were the key catalysts. Moreover, the expansion of coverage for CGM systems during the quarter supported growth. This trend is likely to continue for the rest of 2023. The availability of new sensors like G6 & G7 in new international markets is also boosting revenue growth. Additionally, the glucose monitoring market presents significant commercial opportunities for the company. DexCom’s prospects in alternative markets such as non-intensive diabetes management, hospital, gestational, pre-diabetes and obesity are likely to provide it with a competitive edge in the MedTech space. Apart from making continued advancements in terms of its key strategic objectives, the company continued to have strong new patient additions in the quarter. The expansion of gross and operating margins buoys optimism. However, cut-throat competition in the market for blood & glucose monitoring devices remains another concern.
NASDAQ:DXCMLong
by DEXWireNews
Can DexCom (DXCM) Keep the Earnings Surprise Streak Burning?Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? DexCom (DXCM), which belongs to the Zacks Medical - Instruments industry, could be a great candidate to consider. This medical device company has an established record of topping earnings estimates, especially when looking at the previous two reports. The company boasts an average surprise for the past two quarters of 33.94%. For the most recent quarter, DexCom was expected to post earnings of $0.22 per share, but it reported $0.34 per share instead, representing a surprise of 54.55%. For the previous quarter, the consensus estimate was $0.15 per share, while it actually produced $0.17 per share, a surprise of 13.33%. With this earnings history in mind, recent estimates have been moving higher for DexCom. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank. Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven. The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. DexCom currently has an Earnings ESP of +7.39%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner. We expect the company's next earnings report to be released on October 26, 2023.
NASDAQ:DXCMLong
by DEXWireNews
DXCM WCA -Cup and Handle Company: Dexcom Inc. Ticker: DXCM Exchange: NASDAQ Sector: Health Technology Introduction: Our technical analysis today concentrates on Dexcom Inc. (DXCM), a prominent name in the Health Technology sector, listed on the NASDAQ. A potential Cup and Handle pattern, serving as a reversal formation, has been forming on the weekly chart, suggesting a promising setup for bullish traders. Cup and Handle Pattern: The Cup and Handle pattern typically emerges during a period of consolidation, signifying a potential bullish reversal or continuation. It's recognized by a "cup" formation, followed by a smaller "handle". Analysis: Previously, Dexcom was experiencing a clear downward trend, represented by the blue diagonal line. However, the trend appears to be changing, with the price now consolidating in a Cup and Handle pattern. Though the handle's size is slightly larger than the norm, the well-defined horizontal resistance at 125.58 lends credibility to the pattern's significance. The price is standing above the 200 EMA, confirming a bullish environment. If the price breaks above the horizontal resistance, it could present an excellent opportunity for a long position. The subsequent price target is projected at 184.24, indicating a potential upside of approximately 46.69%. Conclusion: The weekly chart of Dexcom reveals an interesting Cup and Handle pattern, hinting at a potential bullish reversal. As such, this setup could provide a favorable long trading opportunity. Disclaimer: This analysis is not financial advice and is intended for educational purposes only. Always do your own research and consult with a financial advisor before making investment decisions. If you found this analysis helpful, please consider liking, sharing, and following for more insights. Wishing you profitable trading! Best regards, Karim Subhieh
NASDAQ:DXCM
by KarimSubhieh
2
DexCom to breakdown?DexCom - 30d expiry - We look to Sell a break of 108.48 (stop at 113.03) We are trading at overbought extremes. Although the bulls are in control, the stalling positive momentum indicates a turnaround is possible. A break of the recent low at 108.68 should result in a further move lower. This stock has seen poor sales growth. Levels above 122 continue to attract sellers. Our profit targets will be 97.11 and 95.11 Resistance: 118.00 / 120.00 / 125.55 Support: 108.68 / 105.00 / 100.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NASDAQ:DXCMShort
by VantageMarkets
Two healthcare leaders, which one is best to own? NASDAQ:PODD & NASDAQ:DXCM are leading the sectors recovery. Both are in the Medical Products Industry for diabetes. Insulent (PODD) normally outperforms DexCom (DXCM) during and after a correction. Then, when they are in sustained uptrends, DXCM outperforms. For the recent correction, PODD has a -45% deep base while DXCM has a -58%. PODD bottmed 4 weeks before DXCM, but DXCM has rallied +74% and PODD +65% since. So, it really depends on your strategy. If you are looking for aplha then NASDAQ:DXCM is the stock for you but, if you prefer low beta then NASDAQ:PODD is better. Remember that aplha plays in both ways! Which are you trading? I'll trade the first that makes a new high.
NASDAQ:PODDLong
by dpuleo19
DXCM: Bottom?DexCom Short Term - We look to Buy at 74.01 (stop at 60.52) A bullish reverse Head and Shoulders is forming. This is positive for sentiment and the uptrend has potential to return. There is scope for mild selling at the open but losses should be limited. Support is located at 70.00 and should stem dips to this area. Dip buying offers good risk/reward. Our profit targets will be 115.47 and 120.00 Resistance: 116.00 / 135.00 / 164.00 Support: 70.00 / 46.00 / 11.00 Please be advised that the information presented on TradingView is provided to Vantage (‘Vantage Global Limited’, ‘we’) by a third-party provider (‘Signal Centre’). Please be reminded that you are solely responsible for the trading decisions on your account. There is a very high degree of risk involved in trading. Any information and/or content is intended entirely for research, educational and informational purposes only and does not constitute investment or consultation advice or investment strategy. The information is not tailored to the investment needs of any specific person and therefore does not involve a consideration of any of the investment objectives, financial situation or needs of any viewer that may receive it. Kindly also note that past performance is not a reliable indicator of future results. Actual results may differ materially from those anticipated in forward-looking or past performance statements. We assume no liability as to the accuracy or completeness of any of the information and/or content provided herein and the Company cannot be held responsible for any omission, mistake nor for any loss or damage including without limitation to any loss of profit which may arise from reliance on any information supplied by Signal Centre.
NASDAQ:DXCMLong
by VantageMarkets
$DXCM: $375 Price Target ShortFirst off, please don't take anything I say seriously or as financial advice. As always, this is on opinion basis. That being said, let me get into a few key points. Dexcom very recently faced a 52 week high, had positive quarterly earnings, is on a bullish run, outperformed other stocks in the same sector, continues stable growth and has a strong buy rating. It does have some long potential as well, given it is a 2800+ employee company. However, given its long bullish run, I think there is a small chance it could be tipping off. That being said, for a quick profit target, I suggest a $375 short and a reinvestment in some higher growth (but maybe higher risk) stocks.
NASDAQ:DXCMShort
by gamer456148